XoGlo (placental mesenchymal stem cell-based exosomes) / Kimera - LARVOL DELTA

Kimera Labs Files First FDA Investigational New Drug (IND) Application Using XoGlo for Treatment of ARDS Secondary to COVID-19 (PRNewswire) - "Kimera® Labs Inc...announces the filing of an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera's first-in-class XoGlo® isolated placental mesenchymal stem cell-based exosomes....The Company is proposing a 160 patient clinical trial in a non-hospital ambulatory setting."

IND • Infectious Disease • Novel Coronavirus Disease